Inhibition of Mek 1/2 kinase activity and stimulation of melanogenesis by 5,7-dimethoxycoumarin treatment of melanoma cells

International Journal of Oncology

Volumn 34, Issue 6, 2009, Pages 1727-1735

  Alesiani, Daniela ^a   Ciccon, Rosella ^a   Mattei, Maurizio ^a   Bei, Roberto ^a   Canini, Antonella ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

5,7 dimethoxycoumarin; cAMP signalling pathway Mek 1 2 inhibition; Melanogenesis

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 5,7 DIMETHOXYCOUMARIN; COUMARIN DERIVATIVE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; MELANIN; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MONOPHENOL MONOOXYGENASE; PROTOPORPHYRIN; RAF PROTEIN; RAS PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELL MATURATION; CELL PROLIFERATION; CELL STIMULATION; CELL SURVIVAL; CELL TYPE; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; GENETIC CODE; GROWTH INHIBITION; HUMAN; HUMAN CELL; MELANOGENESIS; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STABILITY; PROTEIN SYNTHESIS; TRANSCRIPTION REGULATION;

ANIMALS; BLOTTING, WESTERN; BUTADIENES; CELL DIFFERENTIATION; COUMARINS; CYCLIC AMP; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; DRUG SYNERGISM; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOPRECIPITATION; MAP KINASE KINASE 1; MAP KINASE KINASE 2; MELANINS; MELANOMA; MICE; MICROPHTHALMIA-ASSOCIATED TRANSCRIPTION FACTOR; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NITRILES; RAF KINASES; RAS PROTEINS; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 67649427313     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000303     Document Type: Article

References (47)

1. Egan D, O'Kennedy R, Moran E, Cox D, Prosser E and Thornes RD: The pharmacology, metabolism, analysis, and applications of coumarin and coumarin-related compounds. Drug Metab Rev 22: 503-529, 1990.
2. Maucher A, Kager M and von Angerer E: Evaluation of the antitumour activity of coumarin in prostrate cancer models. J Cancer Res Clin Oncol 119: 150-154, 1993.
3. Sharma S, Stutzman D, Kellof JG and Steele VE: Screening of potential chemopreventive agents using biochemical markers of carcinogenesis. Cancer Res 54: 5848-5855, 1994.
4. Egan D, James P, Cooke D and O'Kennedy R: Studies on the cytostatic and cytotoxic effects and mode of action of 8-nitro-7-hydroxycoumarin. Cancer Lett 118: 201-211, 1997.
5. Hayes JD, Pulford DJ, Ellis EM, et al: Regulation of rat glutathione S-transferase A5 by cancer chemo-preventative agents: mechanisms of inducible resistance to aflatoxin B1. Chem Biol Interact 111-112: 51-67, 1998.
6. Lake BG: Coumarin metabolism, toxicity and carcinogenicity: relevance for human risk assessment. Food Chem Toxicol 37: 423-453, 1999.
7. Salvatore A, Borkosky S, Willink E and Bardòn A: Toxic effects of lemon peel constituents on Ceratitis capitata. J Chem Ecol 30: 323-333, 2004.
8. Canini A, Alesiani D, D'Arcangelo G and Tagliatesta P: Gas chromatography-mass spectrometry analysis of phenolic compounds from Carica papaya L. leaf. J Food Compost Anal 20: 584-590, 2007.
9. Kawaii S, Tomono Y, Katase E, Ogawa K and Yano M: Isolation of furocoumarins from bergamot fruits as HL-60 differentiation-inducing compounds. J Agric Food Chem 47: 4073-4078, 1999.
10. Prince M, Campbell CT, Robertson TA, Wells AJ and Kleiner HE: Naturally occurring coumarins inhibit 7,12-dimethylbenz[a]anthracene DNA adduct formation in mouse mammary gland. Carcinogenesis 27: 1204-1213, 2006.
11. Alesiani D, Cicconi R, Mattei M, Montesano C, Bei R and Canini A: Cell cycle arrest and differentiation induction by 5,7-dimethoxycoumarin on melanoma cell lines. Int J Oncol 32: 425-434, 2008.
12. Fang JY and Richardson BC: The MAPK signalling pathways and colorectal cancer. Lancet Oncol 6: 322-327, 2005.
13. Hearing VJ and Jimenez M: Analysis of mammalian pigmentation at molecular levels. Pigment Cell Res 2: 75-85, 1989.
14. Mansky KC, Sankar U, Han J and Ostrowski MC: Microphthalmia transcription factor is a target of the p38 MAPK pathway in response to receptor activator of NF-kappa B ligand signaling. J Biol Chem 277: 11077-11083, 2002.
15. Vance KW and Goding CR: The transcription network regulating melanocyte development and melanoma. Pigment Cell Res 17: 318-325, 2004.
16. Kadekaro AL, Kavanagh RJ, Wakamatsu K, Ito S, Pipitone MA and Abdel-Malek ZA: Cutaneous photobiology. The melanocyte vs. the sun: who will win the final round? Pigment Cell Res 16: 434-447, 2003.
17. Edward M, Gold JA and Mackie RM: Different susceptibilities of melanoma cell to retinoic acid-induced changes in melanotic expression. Biochem Biophys Res Commun 155: 773-778, 1988.
18. Leszczyniecka M, Roberts T, Dent P, Grant S and Fisher PB: Differentiation therapy of human cancer: basic science and clinical applications. Pharmacol Ther 90: 105-156, 2001.
19. Ickowicz Schwartz DI, Gozlan Y, Greenbaum L, Babushkina T, Katcoff DJ and Malik Z: Differentiation-dependent photodynamic therapy regulated by porphobilinogen deaminase in B16 melanoma. Br J Cancer 90: 1833-1841, 2004.
20. Ignarro LJ, Ballot B and Wood KS: Regulation of soluble guanylate cyclase activity by porphyrins and metalloporphyrins. J Biol Chem 259: 6201-6207, 1984.
21. Brechler V, Pavoine C, Hanf R, Garbarz E, Fischmeister R and Pecker F: Inhibition by glucagon of the cGMP-inhibited low-Km cAMP phosphodiesterase in heart is mediated by a pertussis toxin-sensitive G-protein. J Biol Chem 267: 15496-15501, 1992.
22. Favata MF, Horiuchi KY, Manos EJ, et al: Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 273: 18623-18632, 1998.
23. Hill SE, Buffey J, Thody AJ, Oliver I, Bleehen SS and Mac Neil S: Investigation of the regulation of pigmentation in alpha-melanocyte-stimulating hormone responsive and unresponsive cultured B16 melanoma cells. Pigment Cell Res 2: 161-166, 1989.
24. Lin CB, Babiarz L, Liebel F, et al: Modulation of microphthalmia-associated transcription factor gene expression alters skin pigmentation. J Invest Dermatol 119: 1330-1340, 2002.
25. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
26. Buscà R and Ballotti R: Cyclic AMP a key messanger in the regulation of skin pigmentation. Pigment Cell Res 13: 60-69, 2000.
27. Wellbrock C and Marais R: Elevated expression of MITF counteracts B-RAF-stimulated melanocyte and melanoma cell proliferation. J Cell Biol 170: 703-708, 2005.
28. Torii S, Yamamoto T, Tsuchiya Y and Nishida E: ERK MAP kinase in G1 cell cycle progression and cancer. Cancer Sci 97: 697-702, 2006.
29. Sharma P, Veeranna Sharma M, Amin ND, et al: Phosphorylation of MEK1 by cdk5/p35 down-regulates the mitogen-activated protein kinase pathway. J Biol Chem 277: 528-534, 2002.
30. Han S, Zhou V, Pan S, et al: Identification of coumarin derivatives as a novel class of allosteric MEK1 inhibitors. Bioorg Med Chem Lett 15: 5467-5473, 2005.
31. Kang NJ, Lee KW, Rogozin EA, et al: Equol, a metabolite of the soybean isoflavone daidzein, inhibits neoplastic cell transformation by targeting the MEK/ERK/p90RSK/activator protein-1 pathway. J Biol Chem 282: 32856-32866, 2007.
32. Costin G-E and Hearing VJ: Human skin pigmentation: melanocytes modulate skin color in response to stress. FASEB J 21: 976-994, 2007.
33. Ito S: A chemist's view of melanogenesis. Pigment Cell Res 16: 230-236, 2003.
34. Hemesath TJ, Price ER, Takemoto C, Badalian T and Fisher DE: MAP kinase links the transcription factor microphtalmia to c-Kit signalling in melanocytes. Nature 391: 298-301, 1998.
35. Carreira S, Goodall J, Aksan I, et al: Mitf cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression. Nature 433: 764-769, 2005.
36. Dumaz N and Marais R: Integrating signals between cAMP and the RAS/RAF/ MEK/ERK signalling pathways. FEBS J 272: 3491-3504, 2005.
37. Gerits N, Kostenko S, Shiryaev A, Johannessen M and Moens U: Relations between the mitogen-activated protein kinase and the cAMP-dependent protein kinase pathways: comradeship and hostility. Cell Signal 20: 1592-1607, 2008.
38. Levy C, Sonnenblick A and Razin E: Role played by microphthalmia transcription factor phosphorylation and its Zip domain in its transcriptional inhibition by PIAS3. Mol Cell Biol 23: 9073-9080, 2003.
39. Ahn JH, Jin SH and Kang HY: LPS induces melanogenesis through p38 MAPK activation in human melanocytes. Arch Dermatol Res 300: 325-329, 2008.
40. Lamoreux ML, Wakamatsu K and Ito S: Interaction of major coat color gene functions in mice as studied by chemical analysis of eumelanin and pheomelanin. Pigment Cell Res 14: 23-31, 2001.
41. Virador VM, Santis C, Furumura M, Kalbacher H and Hearing VJ: Bioactive motifs of agouti signal protein. Exp Cell Res 259: 54-63, 2000.
42. Ortel B, Chen N, Brissette J, Dotto GP, Maytin E and Hasan T: Differentiation-specific increase in ALA-induced protoporphyrin IX accumulation in primary mouse keratinocytes. Br J Cancer 77: 1744-1751, 1998.
43. Schoenfeld N, Mamet R, Nordenberg Y, Shafran M, Babushkin T and Malik Z: Protoporphyrin biosynthesis in melanoma B16 cells stimulated by 5-aminolevulinic acid and chemical inducers: characterization of photodynamic inactivation. Int J Cancer 56: 106-112, 1994.
44. Sato N, Moore BW, Keevey S, Drazba JA, Hasan T and Maytin EV: Vitamin D enhances ALA-induced protoporphyrin IX production and photodynamic cell death in 3-D organotypic cultures of keratinocytes. J Invest Dermatol 127: 925-934, 2006.
45. Siboni G, Amit-Patito I, Weizman E, Waintraub-Porat M, Weitman H, Ehrenberg B and Malik Z: Specificity of photo-sensitizer accumulation in undifferentiated versus differentiated colon carcinoma cells. Cancer Lett 196: 57-64, 2003.
46. Namkoong J, Martino JJ and Chen S: From existing therapies to novel targets: a current view on melanoma. Front Biosci 11: 2081-2092, 2006.
47. Wu J, Wong WWL, Khosravi F, Minden MD and Penn LZ: Blocking the Raf/MEK/ ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis. Cancer Res 64: 6461-6468, 2004.